Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rosti

Showing results (181-190 of 198) with videos related to

Pageof 20
Sort By:
ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.
Leukemia|April 29, 2016
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJ L Steegmann, M Baccarani, M Breccia, et al.
British Journal of Haematology|August 8, 1998
Unrelated donor marrow transplantation for chronic myelogenous leukaemiaG Dini, T Lamparelli, R Rondelli, et al.
Bone Marrow Transplantation|January 1, 1996
Unrelated donor marrow transplantation: initial experience of the Italian bone marrow transplant group (GITMO)G Dini, E Lanino, T Lamparelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2014
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerJ Oldenburg, J Aparicio, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Leukemia|June 20, 2015
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinibF Castagnetti, G Gugliotta, M Breccia, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Blood|November 8, 2001
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic respondersF Bonifazi, A de Vivo, G Rosti, et al.
Pageof 20

Showing results (181-190 of 198) with videos related to

Sort By:
Pageof 20
ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.
Leukemia|April 29, 2016
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJ L Steegmann, M Baccarani, M Breccia, et al.
British Journal of Haematology|August 8, 1998
Unrelated donor marrow transplantation for chronic myelogenous leukaemiaG Dini, T Lamparelli, R Rondelli, et al.
Bone Marrow Transplantation|January 1, 1996
Unrelated donor marrow transplantation: initial experience of the Italian bone marrow transplant group (GITMO)G Dini, E Lanino, T Lamparelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2014
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerJ Oldenburg, J Aparicio, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Leukemia|June 20, 2015
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinibF Castagnetti, G Gugliotta, M Breccia, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Blood|November 8, 2001
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic respondersF Bonifazi, A de Vivo, G Rosti, et al.
Pageof 20